August 10, 2025 a 08:00 am
MRNA: Fundamental Ratio Analysis - Moderna, Inc.
Moderna, Inc., the renowned biotechnology company, is engaged in the discovery, development, and commercialization of mRNA therapeutics and vaccines. They play a significant role in addressing global health challenges, with a strong portfolio focusing on infectious and rare diseases. Investors and analysts closely watch its innovation-driven growth and strategic alliances.
Fundamental Rating
The current fundamental rating of Moderna, Inc. is C+, indicating areas of both strength and potential improvement in its financials.
| Category | Score | Visualization |
|---|---|---|
| Overall | 2 | |
| Discounted Cash Flow | 3 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 3 | |
| Price to Earnings | 1 | |
| Price to Book | 4 |
Historical Rating
Comparison of Moderna's current and past fundamental scores reveals stability over time, with minor fluctuations.
| Date | Overall | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-08 | 2 | 3 | 1 | 1 | 3 | 1 | 4 |
| Previous | 0 | 3 | 1 | 1 | 3 | 1 | 4 |
Analyst Price Targets
Moderna's price target analysis indicates market expectations and peer reviews which contribute to investment decisions.
| High | Low | Median | Consensus |
|---|---|---|---|
| $40 | $26 | $32 | $32.5 |
Stock Chart
Analyst Sentiment
The current consensus among analysts for Moderna stands as 'Hold', reflecting a mixed sentiment based on performance.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 9 | |
| Hold | 13 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Moderna, Inc. holds a crucial position in the biotechnology sector, offering significant opportunities through its innovation in mRNA therapeutics. The company’s strategic alliances and robust vaccine pipeline are positive indicators of future growth. However, potential risks include market competition and regulatory challenges. Investors should weigh these factors while considering the current fundamental ratings and analyst sentiments. Overall, Moderna presents a balanced opportunity with both growth prospects and inherent industry risks.